- Home
- SYRE vs CII Comparison
SYRE vs CII Comparison
Compare SYRE & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- CII
- Stock Information
- Founded
- SYRE 2013
- CII 2004
- Country
- SYRE United States
- CII United States
- Employees
- SYRE N/A
- CII N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- CII Investment Bankers/Brokers/Service
- Sector
- SYRE Health Care
- CII Finance
- Exchange
- SYRE Nasdaq
- CII Nasdaq
- Market Cap
- SYRE 1.1B
- CII 939.1M
- IPO Year
- SYRE 2016
- CII N/A
- Fundamental
- Price
- SYRE $23.56
- CII $23.47
- Analyst Decision
- SYRE Strong Buy
- CII
- Analyst Count
- SYRE 6
- CII 0
- Target Price
- SYRE $57.60
- CII N/A
- AVG Volume (30 Days)
- SYRE 1.3M
- CII 78.8K
- Earning Date
- SYRE 11-06-2025
- CII 01-01-0001
- Dividend Yield
- SYRE N/A
- CII 6.17%
- EPS Growth
- SYRE N/A
- CII N/A
- EPS
- SYRE N/A
- CII N/A
- Revenue
- SYRE N/A
- CII N/A
- Revenue This Year
- SYRE N/A
- CII N/A
- Revenue Next Year
- SYRE N/A
- CII N/A
- P/E Ratio
- SYRE N/A
- CII N/A
- Revenue Growth
- SYRE N/A
- CII N/A
- 52 Week Low
- SYRE $10.91
- CII $16.76
- 52 Week High
- SYRE $40.26
- CII $19.81
- Technical
- Relative Strength Index (RSI)
- SYRE 70.08
- CII 58.31
- Support Level
- SYRE $21.88
- CII $22.87
- Resistance Level
- SYRE $24.02
- CII $23.30
- Average True Range (ATR)
- SYRE 1.62
- CII 0.37
- MACD
- SYRE 0.32
- CII -0.04
- Stochastic Oscillator
- SYRE 93.11
- CII 45.03
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.